COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 ...

Operator: Hello, everyone, and welcome to COMPASS Pathways Second Quarter 2025 Earnings Conference Call. Please note that this call is being recorded. COMPASS Pathways plc (NASDAQ:CMPS) is among the ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 ...

COMPASS Pathways PLC ADR stock grades by Barron's. View CMPS fundamental and sentiment analysis powered by MarketGrader.

Ladies and gentleman thank you for standing by, and welcome to the COMPASS Pathways' Ltd. Fourth Quarter 2024 Investor Call. [Operator Instructions] I would now hand today’s call over to Steve Schultz ...

Screening closed for all sites and final participants being scheduled for dosing On track for top-line 6-week primary endpoint results in late Q2 “We are pleased that recruitment is complete in the ...

Fintel reports that on February 27, 2025, Stifel initiated coverage of COMPASS Pathways plc - Depositary Receipt () (NasdaqGS:CMPS) with a Buy recommendation. As of February 19, 2025, the average ...